Murchinson’s Cytokinetics CYTK Stock Holding History

Murchinson’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-78,795	Closed	-$3.17M	–	69
2025 Q1	$3.17M	Hold	78,795	–	–	0.17%	39
2024 Q4	$3.71M	Sell	78,795 -5,000	-6%	-$260K	1.59%	12
2024 Q3	$4.42M	Hold	83,795	–	–	1.2%	19
2024 Q2	$4.54M	Sell	83,795 -25,000	-23%	-$1.51M	0.7%	24
2024 Q1	$7.63M	Buy	108,795 +39,356	+57%	+$3.04M	0.64%	23
2023 Q4	$5.8M	Buy	+69,439	New	+$2.51M	1.01%	13

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Murchinson's CYTK Position: Q2 2025 in Review

Murchinson sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 78,795 shares — an estimated $3.17M sold.

Murchinson first reported a position in CYTK in Q4 2023 and held it in 6 quarters. The position peaked at $7.63M in Q1 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Murchinson reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Murchinson sold 78,795 Cytokinetics shares in Q2 2025, an estimated $3.17M.
Murchinson first reported a position in Cytokinetics in Q4 2023 and held it in 6 quarters.
Murchinson's Cytokinetics position peaked at $7.63M in Q1 2024.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Murchinson's 13F filing for Q2 2025, filed 14 Aug 2025.